{"id":"fluarixtm","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Injection site soreness, redness, or swelling"},{"rate":"5–15","effect":"Myalgia (muscle aches)"},{"rate":"5–15","effect":"Headache"},{"rate":"5–10","effect":"Fatigue"},{"rate":"1–5","effect":"Low-grade fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluarix contains inactivated (killed) influenza virus antigens from three or four circulating seasonal flu strains. When administered, it triggers the adaptive immune response, prompting B cells to produce neutralizing antibodies and T cells to develop cellular immunity against the included viral strains. This immune memory protects against infection or reduces disease severity upon exposure to matching influenza viruses.","oneSentence":"Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:36.739Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children ≥6 months of age"}]},"trialDetails":[{"nctId":"NCT00540228","phase":"PHASE2","title":"Study to Evaluate an Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-05","conditions":"Influenza","enrollment":1006},{"nctId":"NCT00750360","phase":"PHASE4","title":"Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-10-03","conditions":"Influenza","enrollment":883},{"nctId":"NCT01204671","phase":"PHASE3","title":"Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Influenza","enrollment":4659},{"nctId":"NCT00920374","phase":"PHASE3","title":"A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-16","conditions":"Influenza","enrollment":118},{"nctId":"NCT00992784","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-15","conditions":"Influenza","enrollment":370},{"nctId":"NCT01196988","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Influenza","enrollment":3027},{"nctId":"NCT01190215","phase":"PHASE4","title":"Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Influenza","enrollment":77},{"nctId":"NCT00385840","phase":"PHASE2","title":"Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10-20","conditions":"Influenza","enrollment":678},{"nctId":"NCT00321373","phase":"PHASE2","title":"Study to Evaluate an Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-11","conditions":"Influenza","enrollment":1220},{"nctId":"NCT00321763","phase":"PHASE2","title":"Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-27","conditions":"Influenza","enrollment":3124},{"nctId":"NCT01160237","phase":"PHASE3","title":"Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Influenza","enrollment":7},{"nctId":"NCT00866580","phase":"PHASE3","title":"A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2010-05","conditions":"Influenza","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"FluarixTM","genericName":"FluarixTM","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":7,"withResults":7},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}